es Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib RedHill Biopharma Announces Last Patient Out for Phase 2/3 COVID-19 Study of Oral Opaganib

Written by Petra Hegmann on 19th July 2021. Posted in Client News.

• Previous
• Next